Desmond-Hellmann Susan 4

What Happened Susan Desmond‑Hellmann, a member of Pfizer's Board of Directors, was granted 7,686.539 units that represent phantom shares of common stock on April 23, 2026. The units were valued at $26.67 each for a total grant value of $205,000. This was an award (derivative grant) under Pfizer’s non‑employee director compensation plan, not an open‑market purchase or sale.

Key Details

• Transaction date: 2026-04-23; Filing date (Form 4): 2026-04-27. No late filing is indicated in the provided data.
• Grant: 7,686.539 units at $26.67 per unit; total reported value $205,000.
• Shares owned after transaction: Not specified in the provided filing details.
• Footnotes from the filing:
  • F1: Each unit represents one phantom share of common stock.
  • F2: Granted under the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non‑Employee Directors.
  • F3: Units are deferred director compensation, settled in cash or common stock at the director’s election after retirement from the Board.

Context This is a derivative grant of deferred compensation to a non‑employee director. Such awards compensate directors for service and can be settled in cash or stock later; they are not direct purchases or sales that necessarily signal the insider’s view on the stock. For retail investors, purchases are typically more directly informative than deferred awards, which are standard parts of director pay.